CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Lenalidomide 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00792077
NCT00792077Phase 2Completed
CompareCT.gov

A Pilot Open Label Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy Including Lenalidomide on Cancer Related Sleep Disturbances in Chronic Lymphocytic Leukemia (CLL) and Breast Cancer Patients Experiencing Clinically Significant Fatigue

M.D. Anderson Cancer Center·interventional·Posted Nov 17, 2008·Updated Jul 1, 2021

In Brief

A Phase 2 clinical trial evaluating Lenalidomide for Leukemia and CLL. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if treatments to kill cancer cells including lenalidomide and/or radiation therapy can help to control symptoms such as sleep problems and fatigue in patients with chronic lymphocytic leukemia (CLL) and/or breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, CLL
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 17, 2008
Enrollment StartNov 1, 2008
Primary CompletionAug 3, 2020
TodayJul 2, 2026
Enrollment to primary: 11.8 yearsPosted 17.6 years ago

Interventions

Lenalidomidedrug

5 mg daily for 56 days.